Press Release: So-Young Reports Unaudited Fourth Quarter and Fiscal Year 2025 Financial Results

Dow Jones
昨天

BEIJING, March 25, 2026 /PRNewswire/ -- So-Young International Inc. (Nasdaq: SY) ("So-Young" or the "Company"), the leading aesthetic treatment platform in China connecting consumers with online services and offline treatments, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2025.

Fourth Quarter 2025 Financial Highlights

   -- Total revenues were RMB460.7 million (US$65.9 million[1]), compared with 
      RMB369.2 million in the corresponding period of 2024. The aesthetic 
      treatment services revenues were RMB248.1 million (US$35.5 million), 
      compared with RMB81.3 million in the corresponding period of 2024, 
      exceeding the high end of guidance. 
 
   -- Net loss attributable to So-Young International Inc. was RMB108.8 million 
      (US$15.6 million), compared with net loss attributable to So-Young 
      International Inc. of RMB607.6 million in the same period of 2024. 
 
   -- Non-GAAP net loss attributable to So-Young International Inc.[2] was 
      RMB93.4 million (US$13.2 million), compared with non-GAAP net loss 
      attributable to So-Young International Inc. of RMB53.2 million in the 
      same period of 2024. 

Fourth Quarter 2025 Operational Highlights

   -- The number of verified treatment visits to the branded aesthetic centers 
      for the quarter reached over 125,000, compared with approximately 45,000 
      in the same period of 2024. The number of verified aesthetic treatments 
      performed surpassed 289,400, compared with approximately 107,900 in the 
      same period of 2024. 
 
   -- The number of active users, defined as those who visited branded 
      aesthetic centers at least once during the 12-month period ended on 
      December 31, 2025, exceeded 171,000, compared with approximately 52,700 
      users during the corresponding period in 2024. 
 
   -- The number of core members grew by over 14,500 during the quarter, 
      representing an approximately 39% sequential increase. Both the revenue 
      contribution from core members to aesthetic treatment services and their 
      quarterly repurchase rate exceeded 80%. 
 
   -- As of December 31, 2025, So-Young had 49 fully operational branded 
      aesthetic centers (48 directly-operated, 1 franchised) across fifteen 
      major cities: Beijing, Shanghai, Guangzhou, Shenzhen, Hangzhou, Chengdu, 
      Wuhan, Chongqing, Ningbo, Changsha, Tianjin, Xi'an, Suzhou, Hefei and 
      Kunming. Among them, 25 centers achieved profitability* in the fourth 
      quarter. In addition, 39 centers generated positive quarterly operating 
      cash flow* in the fourth quarter. The following table shows the revenues 
      generated by So-Young aesthetic centers, categorized by their phase of 
      development: 
 
([1]) This press release contains translations of certain Renminbi (RMB) 
amounts into U.S. dollars (US$) solely for the convenience of the reader. 
Unless otherwise specified, all translations of Renminbi amounts into U.S. 
dollar amounts in this press release are made at RMB6.9931 to US$1.00, which 
was the U.S. dollars middle rate announced by the Board of Governors of the 
Federal Reserve System of the United States on December 31, 2025. 
([2]) Non-GAAP net income/(loss) attributable to So-Young International Inc. 
is defined as net income/(loss) attributable to So-Young International Inc. 
excluding share-based compensation expenses, impairment of goodwill and 
long-lived assets attributable to So-Young International Inc., impairment of 
long-term investment attributable to So-Young International Inc., allowance 
for credit loss from loans to investees attributable to So-Young International 
Inc., gain/(loss) on disposal of long-term investment and fair value change of 
long-term investment attributable to So-Young International Inc., and tax 
effects on non-GAAP adjustments. See "Reconciliation of GAAP and Non-GAAP 
Results" at the end of this press release. 
 
 
Phase**                                    Average Revenue 
(Operating         Number of  Revenue      per Center        Average Center 
duration)           Centers    (RMB)       (RMB)             Age (Month) 
-----------------  ---------  -----------  ----------------  ----------------- 
Ramp-up (0-3 
 months)                  13   16,598,000         1,277,000                1.2 
-----------------  ---------  -----------  ----------------  ----------------- 
Growth (4-12 
 months)                  19   88,955,000         4,682,000                7.1 
-----------------  ---------  -----------  ----------------  ----------------- 
Maturity (over 12 
 months)                  17  142,523,000         8,384,000               17.8 
-----------------  ---------  -----------  ----------------  ----------------- 
 
 
* Center-level profitability measures whether an individual aesthetic center 
achieved positive profit in a given period. It is calculated by deducting 
consumable materials costs, personnel costs, center rental expenses, center 
depreciation expenses, and other center-level operating costs from the 
company's self-operated store revenues, before allocation of any back-office 
or mid-office expenses. Quarterly operating cash flow refers to total cash 
collected from orders less center-level operating payments in a given period, 
and excluding operating expense payments made by back-office or mid-office 
departments during the same period. Center-level profitability and quarterly 
operating cash flow are metrics derived from the Company's internal management 
accounts, which have not been audited. 
** For the purposes of this table, "Phase" refers to the length of time since 
commencement of actual operations rather than the legal establishment or 
registration date of a branded aesthetic center. In cases where a center has 
been relocated, merged, or its team and customer base transferred to another 
location, the operating duration of the branded aesthetic center is calculated 
from the commencement date of the predecessor center's operations. Periods 
during which a center is temporarily closed and not conducting external 
operations (e.g., due to renovation or other suspensions of business) are 
excluded from the calculation of operating duration. Branded aesthetic centers 
that have been converted to other uses or are no longer within the reporting 
scope are excluded from the statistics. 
 

Fiscal Year 2025 Financial Highlights

   -- Total revenues were RMB1,523.4 million (US$217.8 million) in fiscal year 
      2025, compared with RMB1,466.7 million in the prior year. 
 
   -- Net loss attributable to So-Young International Inc. was RMB242.3 million 
      (US$34.6 million) in fiscal year 2025, compared with a net loss 
      attributable to So-Young International Inc. of RMB589.5 million in the 
      prior year. 
 
   -- Non-GAAP net loss attributable to So-Young International Inc. was 
      RMB217.1 million (US$31.0 million) in fiscal year 2025, compared with a 
      non-GAAP net loss attributable to So-Young International Inc. of RMB4.7 
      million in the prior year. 

Extension of Share Repurchase Program

The share repurchase program, initially approved on March 18, 2024, authorizing the repurchase of up to US$25 million in ADSs or ordinary shares, has been extended for an additional 12-month period through March 31, 2027. In 2024 and 2025, the Company repurchased approximately 4.8 million ADSs. All other terms remain unchanged.

Mr. Xing Jin, Co-Founder and Chief Executive Officer of So-Young, commented, "In the fourth quarter, our aesthetic center business maintained its strong momentum, solidifying its role as a core growth engine for the Group. We have retained our position as China's leading light medical aesthetics chain by scale, which serves as a clear validation of our business model's strength and sustainability. Looking ahead, we will pursue steady store expansion while prioritizing operational excellence and industry-leading standards. Through strategic alliances with upstream manufacturers and a commitment to genuine product traceability, we are building competitive advantages rooted in both unit economics and trust. We are confident that this disciplined approach will drive sustainable value for our shareholders."

Fourth Quarter 2025 Financial Results

Revenues

Total revenues were RMB460.7 million (US$65.9 million), an increase of 24.8% from RMB369.2 million in the same period of 2024. The increase was primarily due to business expansion of the branded aesthetic centers.

   -- Aesthetic treatment services revenues were RMB248.1 million (US$35.5 
      million), an increase of 205.3% from RMB81.3 million in the same period 
      of 2024. The increase was primarily due to the business expansion of the 
      branded aesthetic centers. 
 
   -- Information and reservation services[3] revenues were RMB125.7 million 
      (US$18.0 million), a decrease of 26.8% from RMB171.6 million in the same 
      period of 2024. The decrease was primarily due to a decrease in the 
      number of medical service providers subscribing to information services 
      on So-Young's platform. 
 
   -- Sales of medical products and maintenance services revenues were RMB69.3 
      million (US$9.9 million), a decrease of 19.9% from RMB86.4 million in the 
      same period of 2024, primarily due to a decrease in the order volume for 
      medical equipment. 
 
   -- Other services revenues were RMB17.7 million (US$2.5 million), a decrease 
      of 40.7% from RMB29.9 million in the same period of 2024, primarily due 
      to a decrease in revenues from So-Young Prime. 
 
([3]) Since the second quarter of 2025, in light of the better monitoring 
business development of branded aesthetic centers, the previous line item 
information, reservation services and others was separated into two line 
items, which are information and reservation services and other services. 
The revenue generated from information and reservation services and other 
services for the fourth quarter of 2024 have also been retrospectively 
updated. The amount reclassified from previous line item information, 
reservation services and others to information and reservation services is 
RMB171.6 million for the fourth quarter of 2024. 
 

Cost of Revenues

Cost of revenues was RMB255.9 million (US$36.6 million), an increase of 67.2% from RMB153.1 million in the fourth quarter of 2024. The increase was primarily due to business expansion of the branded aesthetic centers.

   -- Cost of aesthetic treatment services was RMB189.0 million (US$27.0 
      million), an increase of 189.9% from RMB65.2 million in the fourth 
      quarter of 2024. The increase was primarily due to the business expansion 
      of the branded aesthetic centers. 
 
   -- Cost of information and reservation services[4] was RMB10.1 million 
      (US$1.4 million), a decrease of 50.6% from RMB20.4 million in the fourth 
      quarter of 2024. The decrease was in line with the decrease in revenue 
      generated from information and reservation services. 
 
   -- Cost of medical products sold and maintenance services was RMB41.6 
      million (US$5.9 million), a decrease of 4.0% from RMB43.3 million in the 
      fourth quarter of 2024. The decrease was primarily due to a decrease in 
      costs associated with the sales of medical equipment. 
 
   -- Cost of other services was RMB15.3 million (US$2.2 million), a decrease 
      of 36.7% from RMB24.1 million in the fourth quarter of 2024. The decrease 
      was primarily due to a decrease in costs associated with So-Young Prime. 
 
([4]) Since the second quarter of 2025, the previous line item cost of 
information, reservation services and others was separated into two line 
items, which are cost of information and reservation services and cost of 
other services. Cost of information and reservation services primarily 
consists of expenditures relating to operation of platform business, and the 
remaining cost of information, reservation services and others is reclassified 
into cost of other services. The cost of information and reservation services 
and cost of other services for the fourth quarter of 2024 have also been 
retrospectively reclassified. 
 

Operating Expenses

Total operating expenses were RMB327.7 million (US$46.9 million), a decrease of 59.8% from RMB815.2 million in the fourth quarter of 2024.

   -- Sales and marketing expenses were RMB168.7 million (US$24.1 million), an 
      increase of 25.8% from RMB134.0 million in the fourth quarter of 2024. 
      The increase was primarily attributable to an increase in expenses 
      associated with branding and user acquisition activities for the branded 
      aesthetic centers. 
 
   -- General and administrative expenses were RMB101.9 million (US$14.6 
      million), an increase of 3.5% from RMB98.4 million in the fourth quarter 
      of 2024. The increase was primarily due to the business expansion of the 
      branded aesthetic centers. 
 
   -- Research and development expenses were RMB37.4 million (US$5.4 million), 
      a decrease of 12.4% from RMB42.8 million in the fourth quarter of 2024. 
      The decrease was primarily attributable to improvements in staff 
      efficiency. 
 
   -- Impairment of goodwill and long-lived assets was RMB19.7 million (US$2.8 
      million) in this quarter, representing the amount by which the carrying 
      amount of certain asset exceeds their fair value, based on an annual 
      long-lived assets impairment assessment. Impairment of goodwill was 
      RMB540.0 million in the fourth quarter of 2024. 

Income Tax Benefits/(Expenses)

Income tax benefits were RMB0.6 million (US$0.1 million), compared with income tax expenses of RMB2.1 million in the same period of 2024.

Net Loss Attributable to So-Young International Inc.

Net loss attributable to So-Young International Inc. was RMB108.8 million (US$15.6 million), compared with a net loss attributable to So-Young International Inc. of RMB607.6 million in the fourth quarter of 2024.

Non-GAAP Net Loss Attributable to So-Young International Inc.

Non-GAAP net loss attributable to So-Young International Inc., which excludes the impact of share-based compensation expenses, impairment of goodwill and long-lived assets attributable to So-Young International Inc., impairment of long-term investment attributable to So-Young International Inc., allowance for credit loss from loans to investees attributable to So-Young International Inc., gain/(loss) on disposal of long-term investment and fair value change of long-term investment attributable to So-Young International Inc., and tax effects on non-GAAP adjustments, was RMB93.4 million (US$13.2 million), compared with RMB53.2 million non-GAAP net loss attributable to So-Young International Inc. in the same period of 2024.

Basic and Diluted Loss per ADS

Basic and diluted loss per ADS attributable to ordinary shareholders were RMB1.08 (US$0.15) and RMB1.08 (US$0.15), respectively, compared with basic and diluted loss per ADS attributable to ordinary shareholders of RMB5.92 and RMB5.92, respectively, in the same period of 2024.

Fiscal Year 2025 Financial Results

Revenues

Total revenues were RMB1,523.4 million (US$217.8 million), an increase of 3.9% from RMB1,466.7 million in fiscal year 2024.

   -- Aesthetic treatment services revenues were RMB674.9 million (US$96.5 
      million), an increase of 298.7% from RMB169.3 million in fiscal year 
      2024. The increase was primarily due to the business expansion of the 
      branded aesthetic centers. 
 
   -- Information and reservation services revenues were RMB499.7 million 
      (US$71.5 million), a decrease of 32.2% from RMB736.6 million in fiscal 
      year 2024. The decrease was primarily due to a decrease in the number of 
      medical service providers subscribing to information services on 
      So-Young's platform. 
 
   -- Sales of medical products and maintenance services revenues were RMB267.8 
      million (US$38.3 million), a decrease of 27.2% from RMB368.0 million in 
      fiscal year 2024, primarily due to a decrease in sales of medical 
      equipment. 
 
   -- Other services revenues were RMB81.0 million (US$11.6 million), a 
      decrease of 58.0% from RMB192.8 million in the same period of 2024, 
      primarily due to a decrease in revenues from So-Young Prime. 

Cost of Revenues

Cost of revenues was RMB795.7 million (US$113.8 million), an increase of 40.2% from RMB567.6 million in fiscal year 2024. The increase was primarily due to the business expansion of the branded aesthetic centers.

   -- Cost of aesthetic treatment services was RMB518.7 million (US$74.2 
      million), an increase of 294.2% from RMB131.6 million in fiscal year 
      2024. The increase was primarily due to the business expansion of the 
      branded aesthetic centers. 
 
   -- Cost of information and reservation services was RMB63.0 million (US$9.0 
      million), a decrease of 41.1% from RMB107.0 million in fiscal year 2024. 
      The decrease was in line with the decrease in revenue generated from 
      information and reservation services. 
 
   -- Cost of medical products sold and maintenance services was RMB147.1 
      million (US$21.0 million), a decrease of 19.7% from RMB183.2 million in 
      fiscal year 2024. The decrease was primarily due to a decrease in costs 
      associated with the sales of medical equipment. 
 
   -- Cost of other services was RMB66.9 million (US$9.6 million), a decrease 
      of 54.1% from RMB145.9 million in fiscal year of 2024. The decrease was 
      primarily due to a decrease in costs associated with So-Young Prime. 

Operating Expenses

Total operating expenses were RMB1,013.9 million (US$145.0 million), a decrease of 33.5% from RMB1,523.6 million in fiscal year 2024.

   -- Sales and marketing expenses were RMB528.6 million (US$75.6 million), an 
      increase of 6.9% from RMB494.5 million in fiscal year 2024. The increase 
      was primarily attributable to an increase in expenses associated with 
      branding and user acquisition activities for the branded aesthetic 
      centers. 
 
   -- General and administrative expenses were RMB328.5 million (US$47.0 
      million), an increase of 1.4% from RMB324.1 million in fiscal year 2024. 
      The increase was primarily due to the business expansion of the branded 
      aesthetic centers. 
 
   -- Research and development expenses were RMB137.0 million (US$19.6 million), 
      a decrease of 17.0% from RMB165.0 million in fiscal year 2024. The 
      decrease was primarily attributable to improvements in staff efficiency. 
 
   -- Impairment of goodwill and long-lived assets was RMB19.7 million (US$2.8 
      million) in this year, representing the amount by which the carrying 
      amount of certain asset exceeds their fair value, based on an annual 
      long-lived assets impairment assessment. Impairment of goodwill was 
      RMB540.0 million in fiscal year 2024. 

Income Tax (Expenses)/Benefits

Income tax expenses were RMB0.8 million (US$0.1 million), compared with an income tax benefits of RMB0.9 million in fiscal year 2024.

Net Loss Attributable to So-Young International Inc.

Net loss attributable to So-Young International Inc. was RMB242.3 million (US$34.6 million), compared with a net loss attributable to So-Young International Inc. of RMB589.5 million in fiscal year 2024.

Non-GAAP Net Loss Attributable to So-Young International Inc.

Non-GAAP net loss attributable to So-Young International Inc., which excludes the impact of share-based compensation expenses, impairment of goodwill and long-lived assets attributable to So-Young International Inc., impairment of long-term investment attributable to So-Young International Inc., allowance for credit loss from loans to investees attributable to So-Young International Inc., gain/(loss) on disposal of long-term investment and fair value change of long-term investment attributable to So-Young International Inc., and tax effects on non-GAAP adjustments, was RMB217.1 million (US$31.0 million), compared with a non-GAAP net loss attributable to So-Young International Inc. of RMB4.7 million in fiscal year 2024.

Basic and Diluted Loss per ADS

Basic and diluted loss per ADS attributable to ordinary shareholders were RMB2.39 (US$0.34) and RMB2.39 (US$0.34), respectively, compared with basic and diluted loss per ADS attributable to ordinary shareholders of RMB5.72 and RMB5.72 in fiscal year 2024.

Cash and Cash Equivalents, Restricted Cash and Term Deposits, Term Deposits and Short-Term Investments

As of December 31, 2025, cash and cash equivalents, restricted cash and term deposits, term deposits and short-term investments were RMB936.4 million (US$133.9 million), compared with RMB1,253.2 million as of December 31, 2024, primarily due to an increase of investment in branded aesthetic centers.

Business Outlook

For the first quarter of 2026, So-Young expects aesthetic treatment services revenues to be between RMB268.0 million (US$38.3 million) and RMB278.0 million (US$39.8 million), representing a 171.2% to 181.3% increase from the same period in 2025. The above outlook is based on the current market conditions and reflects the Company's preliminary estimates of market and operating conditions, as well as customer demand, which are all subject to change.

Non-GAAP Financial Measures

To supplement the financial measures prepared in accordance with generally accepted accounting principles in the United States, or GAAP, this press release presents non-GAAP income/(loss) from operations and non-GAAP net income/(loss) attributable to So-Young International Inc. by excluding share-based compensation expenses and impairment of goodwill and long-lived assets from income/(loss) from operations, and excluding share-based compensation expenses, impairment of goodwill and long-lived assets, impairment of long-term investment, allowance for credit loss from loans to investees, gain/(loss) on disposal of long-term investment and fair value change of long-term investment and tax effects on non-GAAP adjustments from net income/(loss) attributable to So-Young International Inc., respectively. Starting from the fourth quarter of 2024, the Company newly included impairment of long-term investment, allowance for credit loss from loans to investees, gain/(loss) on disposal of long-term investment and fair value change of long-term investment and tax effects on non-GAAP adjustments as additional adjustments in its non-GAAP financial measures, which may result in differences from previously disclosed non-GAAP figures.

The Company believes these non-GAAP financial measures are important to help investors understand the Company's operating and financial performance, compare business trends among different reporting periods on a consistent basis and assess the Company's core operating results, as they exclude certain expenses (i) that are not expected to result in cash payments or (ii) that are non-recurring in nature or may not be indicative of the Company's core operating results and business outlook. The use of the above non-GAAP financial measures has certain limitations. Share-based compensation expenses, the impairment of goodwill and long-lived assets, impairment of long-term investment and allowance for credit loss from loans to investees are non-cash in nature. Gain/(loss) on disposal of long-term investment and fair value change of long-term investment are non-recurring in nature. And, in substance, both impairment of long-term investment and allowance for credit loss from loans to investees are impairment of investment. All these are not reflected in the presentation of the non-GAAP financial measures, but should be considered in the overall evaluation of the Company's results. The Company compensates for these limitations by providing the relevant disclosure of its share-based compensation expenses, impairment of goodwill and long-lived assets, impairment of long-term investment, allowance for credit loss from loans to investees, gain/(loss) on disposal of long-term investment and fair value change of long-term investment and tax effects on non-GAAP adjustments in the reconciliations to the most directly comparable GAAP financial measures, which should be considered when evaluating the Company's performance. These non-GAAP financial measures should be considered in addition to financial measures prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, financial measures prepared in accordance with GAAP. Reconciliation of each of these non-GAAP financial measures to the most directly comparable GAAP financial measure is set forth at the end of this release.

Conference Call Information

So-Young's management will hold an earnings conference call on Wednesday, March 25, 2026, at 7:30 AM U.S. Eastern Time (7:30 PM on the same day, Beijing/Hong Kong Time). Dial-in details for the earnings conference call are as follows:

 
International:    +1-412-902-4272 
Mainland China:   4001-201203 
US:               +1-888-346-8982 
Hong Kong:        +852-800-905-945 
Passcode:         So Young 
 

A telephone replay will be available two hours after the conclusion of the conference call through 23:59 U.S. Eastern Time, April 1, 2026. The dial-in details are:

 
International:   +1-412-317-0088 
US:              +1-855-669-9658 
Passcode:        5232304 
 

Additionally, a live and archived webcast of this conference call will be available at http://ir.soyoung.com.

About So-Young International Inc.

So-Young International Inc. (Nasdaq: SY) ("So-Young" or the "Company") is the leading aesthetic treatment platform in China connecting consumers with online services and offline treatments. The Company provides access to aesthetic treatments through its online platform and branded aesthetic centers, offering curated treatment information, facilitating online reservations, delivering high-quality treatments, and developing, producing and distributing optoelectronic medical equipment and injectable products. With its strong brand recognition, digital reach, affordable treatments and efficient supply chain, So-Young is well-positioned to serve its audience over the long term and grow along the medical aesthetic value chain.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Among other things, the Financial Guidance and quotations from management in this announcement, as well as So-Young's strategic and operational plans, contain forward-looking statements. So-Young may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about So-Young's beliefs and expectations, are forward-looking statements. Forward looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: So-Young's strategies; So-Young's future business development, financial condition and results of operations; So-Young's ability to retain and increase the number of users and medical service providers, and expand its service offerings; competition in the online medical aesthetic service industry; changes in So-Young's revenues, costs or expenditures; Chinese governmental policies and regulations relating to the online medical aesthetic service industry, general economic and business conditions globally and in China; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in the Company's filings with the Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of the press release, and So-Young undertakes no duty to update such information, except as required under applicable law.

For more information, please contact:

So-Young

Investor Relations

Ms. Mona Qiao

Phone: +86-10-8790-2012

E-mail: ir@soyoung.com

Christensen

Ms. Charlie Chi

Phone: +86-10-5900-1548

(MORE TO FOLLOW) Dow Jones Newswires

March 25, 2026 05:15 ET (09:15 GMT)

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10